Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.01 USD
Change Today +0.04 / 0.17%
Volume 138.0K
QDEL On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Open
$23.04
Previous Close
$22.97
Day High
$23.11
Day Low
$22.75
52 Week High
01/8/15 - $29.38
52 Week Low
07/10/14 - $20.65
Market Cap
793.7M
Average Volume 10 Days
292.5K
EPS TTM
$0.05
Shares Outstanding
34.5M
EX-Date
--
P/E TM
469.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia Respiratory Syncytial Virus (RSV) and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

610 Employees
Last Reported Date: 02/24/15
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $524.4K
Chief Financial Officer
Total Annual Compensation: $331.9K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Research and Develop...
Total Annual Compensation: $195.5K
Senior Vice President of Business Development...
Total Annual Compensation: $334.3K
Compensation as of Fiscal Year 2014.

quidel corp (QDEL) Key Developments

Quidel Corporation Announces the Resignation of Mark Smits as Senior Vice President, Commercial Operations, North America, Effective June 30, 2015

On June 17, 2015, Mr. Mark Smits notified Quidel Corporation of his decision to resign and retire from his position with the company as Senior Vice President, Commercial Operations, North America. The effective date of Mr. Smits's resignation from his position is June 30, 2015.

Quidel Corporation Enters into Amendment No. 3 to its Amended and Restated Credit Agreement

On June 4, 2015, Quidel Corporation entered into Amendment No. 3 to its Amended and Restated Credit Agreement dated as of August 10, 2012. Amendment No. 3 narrows the definition of Change of Control" in the Credit Agreement by removing the provision that certain changes in the composition of the board of directors of the Company would constitute a change of control.

Quidel Corp. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 02:00 PM

Quidel Corp. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 02:00 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Douglas C. Bryant, Chief Executive Officer, President and Director, Randall J. Steward, Chief Financial Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $23.01 USD +0.04

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $8.91 USD +0.16
Luminex Corp $17.16 USD -0.17
Meridian Bioscience Inc $18.31 USD -0.25
OraSure Technologies Inc $5.14 USD -0.23
T2 Biosystems Inc $15.52 USD -0.18
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 3.1x
Price/Cash Flow 109.2x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.